These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 19530907)

  • 1. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.
    de Martimprey H; Vauthier C; Malvy C; Couvreur P
    Eur J Pharm Biopharm; 2009 Mar; 71(3):490-504. PubMed ID: 18977435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
    Fattal E; Bochot A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to successful delivery of short interfering RNA after systemic administration.
    White PJ
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1371-6. PubMed ID: 18565190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
    Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
    J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
    Lu PY; Xie FY; Woodle MC
    Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
    Griesenbach U; Kitson C; Escudero Garcia S; Farley R; Singh C; Somerton L; Painter H; Smith RL; Gill DR; Hyde SC; Chow YH; Hu J; Gray M; Edbrooke M; Ogilvie V; MacGregor G; Scheule RK; Cheng SH; Caplen NJ; Alton EW
    Respir Res; 2006 Feb; 7(1):26. PubMed ID: 16480492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical modification of gene silencing oligonucleotides for drug discovery and development.
    Chen X; Dudgeon N; Shen L; Wang JH
    Drug Discov Today; 2005 Apr; 10(8):587-93. PubMed ID: 15837602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.